8-K: OmniAb Reports First Quarter 2024 Financial Results with Revenue Decline but Pipeline Progress

OmniAb's first quarter 2024 revenue decreased significantly year-over-year, primarily due to a large milestone payment in the prior year, but the company added new partnerships and saw progress in its partnered programs.

Summary

• OmniAb reported a first quarter 2024 revenue of $3.8 million, a significant decrease from $16.9 million in the same period of 2023.
• The revenue decline is primarily attributed to a $10 million milestone payment recognized in Q1 2023 related to the first commercial sale of TECVAYLI in the EU, and lower service revenue due to the completion of discovery work on certain ion channel programs.
• Research and development expenses increased to $14.6 million, up from $13.8 million in Q1 2023, mainly due to higher personnel costs.
• The company's net loss for the quarter was $19.0 million, or $0.19 per share, compared to a net loss of $6.1 million, or $0.06 per share, in the first quarter of 2023.
• As of March 31, 2024, OmniAb had $69.0 million in cash, cash equivalents, and short-term investments.
• OmniAb added three new platform license agreements in the first quarter, bringing the total active partners to 80.
• The company has 327 active programs, including 31 OmniAb-derived programs in clinical development or being commercialized.

Sentiment

Score: 5

Explanation: The document presents mixed signals. While there is progress in partnerships and clinical programs, the significant revenue decline and increased net loss are concerning. The company's future outlook is cautiously optimistic, but there are clear risks and challenges ahead.

Positives

• OmniAb added three new platform license agreements in the first quarter of 2024, expanding its partnership base.
• The company has a large number of active programs (327), indicating a strong pipeline of potential future revenue streams.
• Several partnered programs are progressing through clinical trials, with key data readouts expected in the near future.
• OmniAb expects its cash use to be substantially lower in 2025 compared to 2024.
• The company's current cash balance is expected to be sufficient to fund operations for the foreseeable future.
• OmniAb launched the OmnidAb platform in Q4 2023, which is a next-generation transgenic chicken platform for single-domain antibody discovery.

Negatives

• OmniAb's revenue decreased significantly in Q1 2024 compared to Q1 2023, primarily due to the absence of a large milestone payment.
• The company's net loss widened considerably in Q1 2024 compared to the same period last year.
• Research and development expenses increased, contributing to the higher net loss.
• The company experienced lower service revenue due to the completion of discovery work on certain ion channel programs.

Risks

• OmniAb's future success depends on the acceptance of its technology platform by new and existing partners.
• The company's success is also dependent on the eventual development, approval, and commercialization of products developed by its partners, which is outside of OmniAb's direct control.
• Biopharmaceutical development is inherently uncertain, and there are risks associated with changes in technology.
• The company faces competition in the life sciences and biotechnology platform market.
• OmniAb must maintain, protect, and defend its intellectual property rights.
• The company relies on third parties for its business, and their performance could impact OmniAb's operations.
• Unstable market and economic conditions could have adverse consequences on the business, financial condition, and stock price.
• The company may use its capital resources sooner than expected.

Future Outlook

OmniAb expects operating expenses in 2024 to be approximately the same as in 2023, and cash use in 2024 to be relatively similar to 2023, excluding a $35 million milestone payment received in 2023. Cash use in 2025 is expected to be substantially lower than in 2024. The company's current cash balance and cash from operations are expected to provide sufficient capital to fund operations for the foreseeable future.

Management Comments

• Matt Foehr, Chief Executive Officer of OmniAb, stated that the company added three new platform license agreements in the first quarter, bringing the total active partners to 80.
• Matt Foehr also mentioned that the company has built its business upon a differentiated suite of technologies and a highly scalable and leverageable business model.
• Matt Foehr said that they are off to a strong start in 2024 and look forward to continued progress by their partners and expansion of their technology as the year progresses.

Industry Context

This announcement reflects the ongoing challenges and opportunities in the biotechnology sector, where companies like OmniAb are focused on developing innovative technologies for drug discovery. The decrease in revenue due to the absence of a large milestone payment highlights the volatility of revenue streams in this industry, while the progress in partnered programs and new agreements demonstrates the potential for future growth. The focus on next-generation antibody-based therapeutics aligns with broader industry trends in the development of novel treatments.

Comparison to Industry Standards

• OmniAb's revenue decline in Q1 2024 is significant compared to the previous year, which is not uncommon for biotech companies that rely on milestone payments, which can be lumpy and unpredictable. Companies like AbCellera and Ligand Pharmaceuticals also experience fluctuations in revenue based on milestone achievements.
• The increase in R&D expenses is typical for biotech companies in the clinical development phase, as they invest heavily in advancing their programs. This is similar to companies like BioNTech and Moderna, which have seen significant R&D spending as they developed their mRNA technologies.
• The net loss of $19 million is substantial, but not unusual for a company in OmniAb's stage of development. Many biotech companies operate at a loss for several years while they invest in research and development. Companies like CRISPR Therapeutics and Editas Medicine have also reported significant losses as they advance their gene editing technologies.
• The addition of three new platform license agreements is a positive sign for OmniAb, indicating continued interest in their technology. This is comparable to companies like Twist Bioscience, which focuses on synthetic DNA and has seen growth in partnerships and collaborations.
• The progress in partnered programs, with several clinical trial readouts expected, is a key indicator of future potential. This is similar to companies like Arcus Biosciences, which has multiple partnered programs in clinical development.

Stakeholder Impact

• Shareholders may be concerned about the significant decrease in revenue and the increased net loss.
• Employees may be impacted by the company's financial performance, but the company is staffed and resourced to leverage future growth.
• Partners will be interested in the progress of their programs and the potential for future collaborations.
• Customers will be interested in the company's technology and its potential to develop new therapeutics.
• Creditors will be interested in the company's financial stability and its ability to repay its debts.

Next Steps

• OmniAb will continue to advance its partnered programs, with several clinical trial readouts expected in 2024 and 2025.
• The company will focus on expanding its technology and adding new partners and programs.
• OmniAb will present data at the PEGS Boston Conference and Expo on May 15, 2024.
• Multiple partners will present data from programs developed with OmniAb technology at the ASCO Annual Meeting taking place May 31 June 4, 2024.
• Genmab will present a poster at the ASCO Annual Meeting on June 1, 2024.

Key Dates

Keywords

OmniAb, antibody discovery, biologics, therapeutic development, platform technology, clinical trials, partnerships, revenue, net loss, biotechnology, pharmaceutical